Fig. 3.

A bITH-low status was associated with significantly greater survival benefit only in patients treated with atezolizumab. (a & b) Within the atezolizumab-treated arm, the bITH-low patients achieved significantly more favorable overall survival (OS) and progression-free survival (PFS) compared with bITH-high patients. (c & d) Docetaxel-treated patients manifested comparable OS and PFS irrespective of bITH status. (e & f) A significantly lower percentage of bITH-low patients showed progressive disease as the best overall response (BOR) to atezolizumab compared to bITH-high cases, whereas in the docetaxel arm the proportions were highly comparable irrespective of bITH status.